<link rel="stylesheet" href="styles.f3b1fba60ec7970c.css">

The pharmacology of Blinatumomab

A tƩtel rƶvid nƩzete
dc.contributor.advisorMegyeri, Attila
dc.contributor.advisordeptƁltalĆ”nos OrvostudomĆ”nyi Kar::FarmakolĆ³giai Ć©s FarmakoterĆ”piai IntĆ©zet
dc.contributor.authorAliev, Ruslan
dc.contributor.departmentDE--ƁltalƔnos OrvostudomƔnyi Kar
dc.contributor.opponentSzentmiklĆ³si, JĆ³zsef
dc.contributor.opponentHalasi, Barbara
dc.contributor.opponentdeptƁltalĆ”nos OrvostudomĆ”nyi Kar::FarmakolĆ³giai Ć©s FarmakoterĆ”piai IntĆ©zet
dc.contributor.opponentdeptƁltalĆ”nos OrvostudomĆ”nyi Kar::IgazsĆ”gĆ¼gyi Orvostani IntĆ©zet
dc.date.accessioned2025-04-09T12:36:53Z
dc.date.available2025-04-09T12:36:53Z
dc.date.created2025-03-17
dc.description.abstractBlinatumomab is a bispecific T-cell engager (BiTEĀ®) antibody targeting CD19 on B-cells and CD3 on T-cells, designed to treat relapsed or refractory B-cell malignancies. It redirects T-cells to destroy tumor cells, achieving high response rates. The thesis focuses on the mechanism of action of blinatumomab in addition to the latest clinical trails and summarizes their reported results.
dc.description.courseƔltalƔnos orvos
dc.description.courselangangol
dc.description.degreeegysƩges, osztatlan
dc.format.extent26 pages
dc.identifier.urihttps://hdl.handle.net/2437/388973
dc.language.isoen
dc.rights.infoHozzĆ”fĆ©rhető a 2022 decemberi felsőoktatĆ”si tƶrvĆ©nymĆ³dosĆ­tĆ”s Ć©rtelmĆ©ben.
dc.subjectImmunotherapy
dc.subjectblinatumomab
dc.subjectbispecific antibody
dc.subject.dspaceMedicine::Pharmacology
dc.titleThe pharmacology of Blinatumomab

FƔjlok

Eredeti kƶteg (ORIGINAL bundle)

Megjelenƭtve 1 - 1 (Ɩsszesen 1)
BƩlyegkƩp
NĆ©v:
The pharmacology of Blinatumomab.pdf
MĆ©ret:
988,28 KB
FormƔtum:
Adobe Portable Document Format
LetƶltƩs

EngedƩlyek kƶteg

Megjelenƭtve 1 - 1 (Ɩsszesen 1)
BƩlyegkƩp
NĆ©v:
license.txt
MĆ©ret:
1,94 KB
FormƔtum:
Item-specific license agreed upon to submission
LeƭrƔs:
LetƶltƩs

GyűjtemĆ©nyek

Theses (Faculty of Medicine)